NANOTHERAPEUTICS, INC.

Basic Information

13859 Progress Blvd.
ALACHUA, FL, 32615-9403

http://www.nanotherapeutics.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 073438462
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 70


  1. GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine

    Amount: $2,992,765.00

    DESCRIPTION (provided by applicant): Noroviruses are a group of enteropathogenic viruses belonging to the taxonomic family Caliciviridae, which causes approximately 90% of epidemic non-bacterial outbr ...

    SBIR Phase II 2013 Department of Health and Human Services
  2. GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine

    Amount: $2,992,765.00

    DESCRIPTION provided by applicant Noroviruses are a group of enteropathogenic viruses belonging to the taxonomic family Caliciviridae which causes approximately of epidemic non bacterial outbr ...

    SBIR Phase II 2013 Department of Health and Human Services National Institutes of Health

Agency Micro-sites

US Flag An Official Website of the United States Government